CUAMC
RLMD icon

China Universal Asset Management Company’s Relmada Therapeutics RLMD Stock Holding History

China Universal Asset Management Company’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-282
Closed -$10K – 451
2022
Q3 		$10K Buy
+282
New +$7.81K ﹤0.01% 209

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

China Universal Asset Management Company's RLMD Position: Q4 2022 in Review

China Universal Asset Management Company sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 282 shares — an estimated $10K sold.

China Universal Asset Management Company first reported a position in RLMD in Q3 2022 and held it in 1 quarter. The position peaked at $10K in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • China Universal Asset Management Company reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • China Universal Asset Management Company sold 282 Relmada Therapeutics shares in Q4 2022, an estimated $10K.
  • China Universal Asset Management Company first reported a position in Relmada Therapeutics in Q3 2022 and held it in 1 quarter.
  • China Universal Asset Management Company's Relmada Therapeutics position peaked at $10K in Q3 2022.
  • 110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on China Universal Asset Management Company's 13F filing for Q4 2022, filed 31 Jan 2023.